| epirubicin / Generic mfg. |
ACTRN12611000471987: A Comparison of Recurrence After Radical Hepatectomy in Hepatocellular Carcinoma (HCC) Patients Underwent Intraoperative Adjuvant Epirubicin therapy or Not |
|
|
| Not yet recruiting | 4 | 60 | | | Eastern Hepatobiliary Surgery Hospital, Eastern Hepatobiliary Surgery Hospital | hepatocellular carcinoma | | | | |
ChiCTR-TRC-07000033: A randomized controlled trial of traditional Chinese medicine in the treatment of primary liver cancer |
|
|
| Completed | 4 | 1200 | | Advanced liver cancer. 1. TACE; 2. Cinobufotalin 50ml ivgtt. q.d for Day 1 – 10; Kangsaidi 0.75g po. Bid. or Huai-er 20g po. Bid; TCM decoction 100ml po. Bid. Cinobufotalin be used between the first and the second TACE; then use one therapy course every two months or every two months after a year ;TACE for advanced liver cancer. Perform CT or MRI every 1.5 or 2 months after the first TACE，every 2 or 3 months after the second TACE, only if lesions active. If there are contraindications, do not perform TACE. ;Postoperative small hepatocellular carcinoma. Inject epirubicin, fluotouracil, mitomycin, lipiodol in proper left or right hepatic artery and form emulsion embolism with ultra-fluid lipiodol. Perform TACE at one month after radical operation. ;TCM for postoperative small hepatocellular carcinoma. (1) Cinobufotalin 50ml ivgtt. q.d. (2) Cinobufotalin 2 pills po. t.i.d. (3) TCM decoction 100ml po. t.i.d. Use one course (10 days) every 3 months for four courses. | Changhai Hospital, The Second Military Medical University; The Ministry of Science and Technology of People's Republic of China, The Ministry of Science and Technology of People's Republic of China | Hepatocellular carcinoma | | | | |
ChiCTR-TRC-08000300: Preventive effect of postoperative TACE against small hepatocellular carcinoma recurrence |
|
|
| Completed | 4 | 60 | | All patients will accept neither TACE nor other chemotherapy and radiotherapy one month after liver resection. ;All patients will be performed TACE (lipiodol 5ml, epirubicin 20mg, 5FU 500mg, hydroxy camptothecin 10mg)one month after liver resection. | Eastern hepatobiliary surgery hospital; Eastern hepatobiliary surgery hospital, Independently | primary hepatocelullar carcinoma | | | | |
ChiCTR-TRC-08000267: A Clinical Randomized Control Trial of Combination TACE With and Without Low-Molecular-Weight Heparin in Hepatocellular Carcinoma |
|
|
| Completed | 4 | 100 | | no intervention ;hypodermic injection LMWH 4100 IU each 12 hours in 6 weeks; TACE scheme: iodine oil 1.5ml/cm diametre tumour, Epirubicin Hydrochloride injection 20mg, 5-Fu 1g, Carboplatin 150 mg. | Shanghai Eastern Hepatobiliary Surgery Hospital; Ministry of Science and Technology of China, Major projects the National Science and Technology-AIDS and viral hepatitis and other major infectious diseases | Hepatocellular carcinoma | | | | |
ChiCTR-TRC-09000523: A Multicenter Randomized control Study: Arsenic Trioxide plus Transcatheter Arterial Chemoembolization In Patients With Hepatocellular Carcinoma |
|
|
| Completed | 4 | 420 | | Epirubicin ;Arsenic Trioxide ;Epirubicin + Arsenic Trioxide | The first Hospital Affiliated to China Medical University; Level of the institution：, Self-funding | Hepatocellular carcinoma | | | | |
2005-000403-33: Randomized clinical trial to evaluate the predictive accuracy of a geneexpression profile-based test to select patients for preoperativetaxane/anthracycline chemotherapy for stage I-III breast cancer |
|
|
| Ongoing | 4 | 60 | Europe | PACLITAXEL, FLUOROURACIL, CYCLOPHOSPHAMIDE, EPIRUBICIN, TAXOL, FLUOROURACILO FERRER FARMA, GENOXAL, PHARMORUBICIN, TAXOL, FLUOROURACILO FERRER FARMA, GENOXAL, PHARMORUBICIN | GRUPO ESPAÑOL DE INVESTIGACIÓN EN CÁNCER DE MAMA (GEICAM) | Patients with histologically confirmed stage I-III invasive carcinoma of the breastfor whom adjuvant chemotherapy is indicated. | | | | |
2005-004126-56: Observational pharmacokinetic study of doxorubicin and cyclophosphamide in patients with early breast cancer. |
|
|
| Ongoing | 4 | 50 | Europe | Doxorubicin, Cyclophosphamide, Fluorouracil, epirubicin, Fluorouracil, epirubicin | Newcastle upon Tyne Hospitals NHS Trust | Early breast cancer | | | | |
2009-013029-41: Proteomic profile analysis to classify advanced pancreatic adenocarcinoma patients for clinical outcome after treatment with PDXG (cisplatin, docetaxel, capecitabine, gemcitabine) or PEXG (cisplatin, epirubicin, capecitabine, gemcitabine) regimen. |
|
|
| Ongoing | 4 | 100 | Europe | CISPLATINO TEVA, GEMZAR, FARMORUBICINA, XELODA, TAXOTERE, CISPLATINO TEVA, GEMZAR, FARMORUBICINA, XELODA, TAXOTERE | FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR | patients affected by adenocarcinoma at stage III or IV who are candidate to receive upfront chemotherapy according to PDXG or PEXG regimen. | | | | |
ChiCTR-IPR-16007912: Raltitrexed based transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a single-center randomized controlled study |
|
|
| Recruiting | 4 | 200 | | TACE (raltitrexed, epirubicin and oxaliplatin) ;TACE (epirubicin and oxaliplatin) | The First Affiliated Hospital, Sun Yat-sen University; The First Affiliated Hospital, Sun Yat-sen University, Patients and health care units、Study leader | Unresectable Hepatocellular Carcinoma | | | | |
ChiCTR-IPR-14005713: Compare the cardiotoxcity of TC and EC adjuvant chemotherapy in patients with breast cancer: a multi-cetre, controlled, randomized clinical trial |
|
|
| Suspended | 4 | 1146 | | pirarubicin plus cyclophosphamide ;epirubicin plus cyclophosphamide | Cancer Institute and Hospital, Chinese Academy of Medical Sciences;, Shenzhen Main Luck Pharmaceuticals Inc. | breast cancer | | | | |
ChiCTR-IPR-16007759: Cardiotoxicity induced by epirubicin-based chemotherapy for early stage Breast Cancer Patients with Diabetes and the Protection of Dexrazoxane |
|
|
| Recruiting | 4 | 150 | | NDM2 chemotherapy ;DM2 chemotherapy ;chemotherapy plus dexrazoxane | Fourth Hospital of Hebei Medical University; Fourth Hospital of Hebei Medical University, Raise funds independently | tumour and cardiology | | | | |
2017-000641-44: Dose monitoring of commonly used cytostatic drugs for breast cancer |
|
|
| Ongoing | 4 | 250 | Europe | Cyclophosphamide, Epirubicin, Doxorubicin, Docetaxel, Paclitaxel, L01CD01, Concentrate and solvent for concentrate for solution for infusion, Concentrate and solvent for solution for infusion | Karolinska intitutet, Dept. of Oncology, Karolinska University Hospital | Newly diagnosed pre- or post-operative breast cancer, Breast cancer, Diseases [C] - Cancer [C04] | | | | |
| Completed | 4 | 240 | | weekly paclitaxel-epirubicin (PE) ;triweekly 5-uorouracil(5-FU)-epirubicin-cyclophos | West China Hospital of Sichuan University; Level of the institution：, Self-funding | the breast cancer | | | | |
ChiCTR-IPR-16008631: A randomized controlled study of comparing the efficacy and safety of Pegylated liposmal doxorubicin, Epirubicin and Doxorubicin in Diffuse large B cell lymphoma |
|
|
| Not yet recruiting | 4 | 225 | | R-CDOP protocol ;R-CEOP protocol ;R-CHOP protocol | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, self-finacing | Diffuse large B cell lymphoma | | | | |
ChiCTR1800017984: Real-world study for CalliSpheres-loaded microsphere embolization in the treatment of unresectable advanced non-small-cell carcinoma |
|
|
| Not yet recruiting | 4 | 60 | | Arterial infusion of cisplatin and 5-fluorouracil combined with CalliSpheres-loaded microspheres loading with epirubicin for embolization | The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University, self-financing | Non-small-cell carcinoma | | | | |
ChiCTR1800016395: A multicenter, randomized, controlled, trial for the efficacy and safety of hepatic artery chemoembolization (TACE) with LBP or pharmorubicin in the treatment of nonresectable hepatocellular carcinoma |
|
|
| Recruiting | 4 | 380 | | LBP30mg/m2, TACE operation ;Epirubicin 30mg/m2, TACE operation | Zhongshan Hospital Affiliated to Fudan University; Level of the institution：, Hainan Changan International Pharmaceutical Co., Ltd. | Hepatocellular carcinoma | | | | |
ChiCTR-IIR-16008357: The effectiveness and safety of instillation of BCG and alternative BCG protocols for intermediate and high risk non-muscle invasive bladder cancer-Multi-institutional RCT |
|
|
| Recruiting | 4 | 875 | | After TURBT, one immediate instillation of epirubicin and 19 BCG ;After TURBT, one immediate instillation of epirubicin and 15 BCG ;After TURBT, one immediate instillation of epirubicin and 18 more epirubicin | Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Chengdu Institute of Biological Products Co., Ltd., Chengdu Institute of Biological Products Co., Ltd. | bladder cancer | | | | |
ChiCTR-IIR-16007817: The efficacy and saftety of high-dose epirubicin as neoadjuvant chemotherapy in breast cancer of Chinese population: a prospective multicenter clinical study |
|
|
| Not yet recruiting | 4 | 522 | | TEC with high dose of epirubicin (100mg/m2) ;EC-T with high dose of epirubicin (100mg/m2) ;EC-TC with high dose of epirubicin (100mg/m2) | The first affiliated hospital of AnHui Medical University; The first affiliated hospital of AnHui Medical University, Hisunpharm pharmaceutical Co. Ltd. | Breast cancer | | | | |
ChiCTR1900022968: Transarterial chemoembolization with epirubicin-loaded CalliSpheres microspheres in the treatment of hepatocellular carcinoma: a multicenter clinical stud |
|
|
| Not yet recruiting | 4 | 219 | | Transarterial chemoembolization with epirubicin-loaded CalliSpheres microspheres | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Cancer intervention research fund of China health promotion foundation | Liver Cancer | | | | |
ChiCTR-OPC-17011144: A Single Arm, Single Center Clinical Trial: Detecting Circulating Tumor DNA to Predict the Effect of Anthracycline-based Neoadjuvant Chemotherapy For HER-2-negative Middle or High Risk Breast Cancer |
|
|
| Not yet recruiting | 4 | 150 | | Neoadjuvant chemotherapy regimen containing epirubicin | Department of Breast Surgery, the First Affiliated Hospital of Xi’an Jiaotong University; Department of Breast Surgery, the First Affiliated Hospital of Xi’an, Hisun Pfizer Pharmaceuticals Limited Company | Breast Cancer | | | | |
ChiCTR2000036221: Multi-center clinical study of chemoembolization treatment of hepatocellular carcinoma (HCC) under the CPSC microsphere loaded with adriamycin CalliscpSC |
|
|
| Recruiting | 4 | 20 | | Transarterial chemoembolization with epirubicin-loaded CalliSpheres microspheres | Shenzhen Second People's Hospital; Shenzhen Second People's Hospital, The hospital finance | Cancer of the liver | | | | |
ChiCTR2100041984: Transarterial idarubicin versus epirubicin chemoembolization for primary liver cancer: a randomized, single blind, multicenter study |
|
|
| Recruiting | 4 | 240 | | Idarubicin combined with TACE ;Epirubicin combined with TACE | West China Hospital, Sichuan University; West China Hospital, Sichuan University, researchers | Primary liver cancer | | | | |
| Active, not recruiting | 4 | 290 | RoW | Rituximab, Cyclophosphamide, Epirubicin, Vincristine, Prednisone | Ruijin Hospital | Diffuse Large B-cell Lymphoma | 10/22 | 12/24 | | |
ChiCTR2000034758: Idarubicin Hydrochloride and Epiroxorubicin Hydrochloride in the treatment of BCLC-B stage Hepatocellular carcinoma by transhepatic Arterial chemotherapy and Embolization: a randomized, double-blind, parallel controlled multicenter study |
|
|
| Not yet recruiting | 4 | 240 | | DCB +IDARUBICIN ;DCB +EPIRUBICIN | The First Affiliated Hospital of Sun Yat-Sen University; The First Affiliated Hospital of Sun Yat-Sen University, government | Hepatocellular carcinoma | | | | |
PADMA, NCT03355157 / 2016-004482-89: A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - Study). |
|
|
| Recruiting | 4 | 150 | Europe | Palbociclib / Chemotherapy (capecitabine, epirubicin, paclitaxel, vinorelbine) / Endocrine therapy (exemestane, fulvestrant, letrozole, tamoxifen) | German Breast Group, Pfizer, AMS Advanced Medical Services GmbH | Metastatic Breast Cancer | 03/23 | 03/23 | | |
ChiCTR2000040996: Patient-Derived Tumor-Like Cell Clusters for Adjuvant Intravesical Chemotherapy in Patients with Intermediate/High-Risk Non-Muscle Invasive Bladder Cancer: a Randomized Controlled Clinical Trial |
|
|
| Recruiting | 4 | 300 | | Epirubicin ;Screening Drug | The Second Hospital of Tianjin Medical University; The Second Hospital of Tianjin Medical University, self-raised | Bladder Cancer | | | | |
ChiCTR2100044103: Epirubicin-loaded microspheres TACE combined with tocilizumab in the treatment of stage III hepatocellular carcinoma |
|
|
| Recruiting | 4 | 156 | | DEB-TACE ;DEB-TACE combined with IL-6 antibody | Qingdao University Affiliated Hospital; Qilu Hospital of Shandong University, Beijing Medical Award Foundation | Primary liver cancer | | | | |
ChiCTR2100054383: A Real-World Study of the Efficacy and Safety of Liposomal Doxorubicin Versus Epirubicin in AC-T Regimen for Neoadjuvant Chemotherapy in Patients with HER2-Negative Breast Cancer |
|
|
| Not yet recruiting | 4 | 450 | | PLD + cyclophosphamide ;Epirubicin + cyclophosphamide | The Second Affiliated Hospital of Harbin Medical University; The Second Affiliated Hospital of Harbin Medical University, Self-funded | HER2-negative breast cancer | | | | |
NCT02627248: Neoadjuvant Chemotherapy With or Without Huaier Granule in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery |
|
|
| Recruiting | 4 | 200 | RoW | Huaier Granule, Epirubicin, Docetaxel, Cyclophosphamide | Shandong University | Breast Cancer | 10/25 | 10/25 | | |
ChiCTR2000039578: A prospective, open, multicenter, randomized controlled trial for the effect of albumin-bound paclitaxel combined with cisplatin versus epirubicin combined with cyclophosphamide sequential docetaxel neoadjuvant therapy for triple negative breast cancer |
|
|
| Recruiting | 4 | 240 | | Paclitaxel (Albumin Bound）combined with cisplatin ;Epirubicin combined with cyclophosphamide sequential docetaxel | Jiangxi Cancer Hospital; Jiangxi Cancer Hospital, Jiangsu Hengrui Pharmaceutical Co., Ltd | Breast cancer | | | | |
NCT04137640: Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant Chemotherapy |
|
|
| Not yet recruiting | 4 | 152 | RoW | palbociclib combined with letrozole, Endocrine group, epirubicin combined with cyclophosphamide and sequential docetaxel, Chemotherapy group | Shengjing Hospital | Breast Cancer | 11/25 | 05/26 | | |
NCT04136782: Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer |
|
|
| Recruiting | 4 | 110 | RoW | Albumin-bound paclitaxel combined with carboplatin, Albumin-bound paclitaxel+carboplatin group, Epirubicin combined with docetaxel, Epirubicin+docetaxel group | Shengjing Hospital | Breast Cancer | 11/25 | 11/26 | | |
ChiCTR1900026499: Albumin-bound paclitaxel combined with carboplatin versus epirubicin combined with docetaxel as neoadjuvant therapy for triple-negative breast cancer: a multicenter randomized controlled phase IV clinical trial |
|
|
| Not yet recruiting | 4 | 110 | | albumin-bound paclitaxel combined with carboplatin ;epirubicin combined with docetaxel | Shengjing Hospital of China Medical University; 中国医科大学附属盛京医院, Self-financing | Breast Cancer | | | | |
ChiCTR1900026493: Palbociclib combined with letrozole versus epirubicin combined with cyclophosphamide and sequential docetaxel as neoadjuvant chemotherapy for inoperable postmenopausal estrogen receptor-positive breast cancer with low Ki67 expression: a prospective randomized controlled double-blind phase IV trial |
|
|
| Not yet recruiting | 4 | 152 | | palbociclib combined with letrozole ;epirubicin combined with cyclophosphamide and sequential docetaxel | Shengjing Hospital of China Medical University; Shengjing Hospital of China Medical University, Self-financing | Breast Cancer | | | | |
NCT05420454: A Study for the Neoadjuvant Treatment of Breast Cancer |
|
|
| Recruiting | 4 | 1576 | RoW | Docetaxel, Carboplatin, Trastuzumab, Pertuzumab, Nab paclitaxel, Epirubicin, Cyclophosphamide | Second Affiliated Hospital, School of Medicine, Zhejiang University | Breast Cancer | 06/27 | 12/27 | | |
NCT05420467: A Study for the Adjuvant Treatment of Breast Cancer |
|
|
| Recruiting | 4 | 2413 | RoW | Docetaxel, Carboplatin, Trastuzumab, Pertuzumab, Nab paclitaxel, Epirubicin, Cyclophosphamide | Second Affiliated Hospital, School of Medicine, Zhejiang University | Breast Cancer | 07/27 | 12/27 | | |
NCT00005584: Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma |
|
|
| Active, not recruiting | 3 | 1649 | Europe | bleomycin sulfate, ABVD regimen, BEACOPP regimen, epirubicin hydrochloride, prednisone, vinblastine sulfate, radiation therapy | European Organisation for Research and Treatment of Cancer - EORTC, Lymphoma Study Association, UNICANCER | Lymphoma | 05/04 | | | |
GIM2, NCT00433420: Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer |
|
|
| Active, not recruiting | 3 | 2000 | NA | pegfilgrastim, cyclophosphamide, epirubicin hydrochloride, fluorouracil, paclitaxel, adjuvant therapy | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy, Gruppo Italiano Mammella (GIM) | Breast Cancer | 05/06 | 12/25 | | |
2012-000576-42: S1007 is a clinical trial for patients with node positive (1-3 positive nodes) Hormone Receptor-Positive and HER2-Negative Breast Cancer who when tested with the Oncotype DX test are shown to have a recurrence Score (RS) of 25 or Less. Patients will be randomised to receive endocrinetherapy +/- chemotherapy. |
|
|
| Ongoing | 3 | 5000 | Europe | Docetaxel, Cyclophosphamide, 5-FU, doxorubicin, Epirubicin, Paclitaxel, Tamoxifen, Concentrate for solution for infusion, Powder and solution for solution for injection, Injection, Solution for injection/infusion, Powder for solution for infusion, Tablet, Tamoxifen | Cancer Trials Ireland, Genomic Health | Patients with 1-3 positive Nodes, Hormone Receptor-Positive and Her2-Negative Breast Cancer with recurrence Score (RS) of 25 or Less, Patients with 1-3 positive Nodes, Hormone Receptor-Positive and Her2-Negative Breast Cancer with recurrence Score (RS) of 25 or Less, Diseases [C] - Cancer [C04] | | | | |
2013-004307-39: Response to Optimal Selection of neo-adjuvant Chemotherapy in Operable breast cancer |
|
|
| Ongoing | 3 | 1050 | Europe | 5-fluorouracil, Epirubicin, Cyclophosphamide, Docetaxel, Trastuzumab, 5-fluorouracil, Epirubicin, Cyclophosphamide, Docetaxel, Trastuzumab, Infusion, Solution for injection in cartridge, | University of Birmingham, Cancer Research UK, Celgene | Breast cancer, Breast cancer, Diseases [C] - Cancer [C04] | | | | |
ACTRN12613000119796: Neoadjuvant chemotherapy with nab-paclitaxel in women with HER2-negative high-risk breast cancer |
|
|
| Active, not recruiting | 3 | 632 | | | Fondazione Michelangelo, Investigator Initiated Research Grant from Celgene | Breast Cancer | | | | |
2007-003810-32: Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial. |
|
|
| Ongoing | 3 | 120 | Europe | Fluorouracil, Tamoxifen, Docetaxel, Epirubicin, Paclitaxel, Cyclophosphamide, Doxorubicin, Methotrexate, Anastrozole, Letrozole, Exemestane, Chemotherapy, Hormone Therapy, Chemotherapy, Hormone Therapy | the All-Ireland cooperative oncology research group (ICORG) | Patients will be ER and/or PR-positive, axillary node negative, HER2 negative breast cancer patients. | | | | |
2010-023484-17: Sarcomas de partes blandas localizados de alto riesgo de extremidades y pared de tronco en adultos: un enfoque integrador que incluye tratamiento con medicamentos antitumorales estándar comparado con tratamientos específicos para las diferentes variedades histológicas como primer tratamiento. |
|
|
| Ongoing | 3 | 250 | Europe | epirrubicina, ifosfamida, Gemcitabina, Docetaxel, Etoposido, FARMIBLASTINA, Dacarbazina, epirubicin, ifosfamide, gemcitabine, docetaksel, etoposide, dacarbazine, epirubicin, ifosfamide, gemcitabine, docetaksel, etoposide, dacarbazine | ITALIAN SARCOMA GROUP, Grupo Español de Investigación en Sarcomas, Italian Sarcoma Group, , Grupo Español de Investigación en Sarcomas, NHS (diagnostic and therapeutic procedures), Eurosarc, funded by project/grant FP7 | High risk localized soft tissue sarcomas typical of the adult | | | | |
2011-001858-28: A clinical trial for people who have cancer of the food pipe and junction of the food pipe and stomach, to compare chemotherapy before and after surgery, with chemotherapy with radiotherapy before surgery. |
|
|
| Ongoing | 3 | 378 | Europe | Epirubicin, Cisplatin, 5 Fluorouracil, Capecitabine, Paclitaxel, Carboplatin, Oxaliplatin, Carboplatin, Cisplatin, Epirubicin, Capecitabine, Fluorouracil, Paclitaxel, Eloxatin, Carboplatin, Cisplatin, Epirubicin, Capecitabine, Fluorouracil, Paclitaxel, Eloxatin | ICORG, ICORG- All Ireland Cooperative Oncology Research Group, ICORG, | Adenocarcinoma of the oesophagus and oesophago-gastric junction | | | | |
| Completed | 3 | 632 | Europe, RoW | Abraxane, Nab-paclitaxel, Paclitaxel, No specific brand name | Fondazione Michelangelo | Breast Cancer | 09/16 | 03/23 | | |
|
APHINITY, NCT01358877 / 2010-022902-41: A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer |
|
|
| Active, not recruiting | 3 | 4804 | Europe, Canada, Japan, US, RoW | 5-Fluorouracil, Carboplatin, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin, Paclitaxel, Pertuzumab, Perjeta®, Placebo, Trastuzumab, Herceptin® | Hoffmann-La Roche, Genentech, Inc., Breast International Group | Breast Cancer | 12/16 | 11/24 | | |
|
|
|
|
|
PERS, NCT03006614: Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer |
|
|
| Recruiting | 3 | 320 | RoW | NVB, vinorelbine, EPI, epirubicin, DDP, cisplatin, CAP, capecitabine, GEM, gemcitabine, H, Trastuzumab, CTX, cyclophosphamidem, T, docetaxel | Shi Yanxia | Breast Cancer Model, Effects of Chemotherapy, Breast Cancer | 03/18 | 03/23 | | |
| Active, not recruiting | 3 | 788 | Europe | cisplatin+capecitabine, radiotherapy, epirubicin+cisplatin+capecitabine | Dutch Colorectal Cancer Group, The Netherlands Cancer Institute, Roche Pharma AG | Gastric Cancer | 12/18 | 12/25 | | |
SVOSA, NCT02338518: Comparison of SEEOX and SOX Regimens in Stage ⅢB/ⅢC Gastric Cancer Patients |
|
|
| Active, not recruiting | 3 | 297 | RoW | oxaliplatin, etoposide, pharmorubicin, epirubicin, S-1 | Jinling Hospital, China | Stomach Neoplasms, Gastric Cancer | 05/19 | 10/23 | | |
2018-002080-25: A TRANSLATIONAL RANDOMIZED PHASE III STUDY EXPLORING THE EFFECT OF THE ADDITION OF CAPECITABINE TO CARBOPLATINUM BASED CHEMOTHERAPY IN EARLY “TRIPLE NEGATIVE” BREAST CANCER. |
|
|
| Not yet recruiting | 3 | 920 | Europe | Epirubicin, Sendoxan, Carboplatin, Capecitabine, Paclitaxel, KEYTRUDA, Not applicable., Concentrate for solution for infusion, Powder for solution for infusion, Film-coated tablet, Concentrate and solvent for concentrate for solution for infusion, Concentrate for solution for injection, Epirubicin, Sendoxan., Carboplatin, Capecitabine, Paclitaxel, KEYTRUDA | Skåne University Hospital, Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital., Vetenskapsrådet | Early triple negative breast cancer., Early triple negative breast cancer., Diseases [C] - Cancer [C04] | | | | |
NCT02363400: A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA |
|
|
| Enrolling by invitation | 3 | 147 | RoW | MEP, epirubicin, cisplatin, oral Tegafur-uracil, mitomycin-C | National Health Research Institutes, Taiwan, National Taiwan University Hospital, Mackay Memorial Hospital, China Medical University Hospital, National Cheng-Kung University Hospital, Kaohsiung Veterans General Hospital., Taichung Veterans General Hospital | Nasopharyngeal Carcinoma | 12/19 | 12/22 | | |
NCT02879513: Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy |
|
|
| Recruiting | 3 | 290 | RoW | Paclitaxel, Taxol, Cisplatin, Epirubicin, Cyclophosphamide, 5-fluoruracil, 5-FU | RenJi Hospital | Invasive Ductal Breast Cancer, Tubular Breast Cancer, Mucinous Breast Cancer, Inflammatory Breast Cancer | 06/20 | 12/22 | | |
2019-003543-30: A study to test the effect of chemotherapy before surgery compared to surgery alone in patients with high risk retroperitoneal sarcoma |
|
|
| Ongoing | 3 | 250 | Europe | Doxorubicin, Epirubicin, Dacarbazin, Ifosfamide, [Doxorubicin], [Epirubicin], [Dacarbazin], [Ifosfamide], Solution for infusion, Solution for injection/infusion, Powder for solution for injection/infusion | European Organisation for Research and Treatment of Cancer, EORTC AISBL/IVZW, European Organisation for the Research and Treatment of Cancer, Anticancer fund | Primary high risk leiomyosarcoma or Liposarcoma of retroperitoneal space or infra-peritoneal spaces of pelvis, Retroperitoneal sarcoma: a sarcoma developed in the back of the belly, next to the kidneys, in a relatively “hidden” location known as the retroperitoneum., Diseases [C] - Cancer [C04] | | | | |
PANSY, NCT04193059: Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer |
|
|
| Recruiting | 3 | 1560 | RoW | Paclitaxel, Carboplatin, Epirubicin, Cyclophosphamide, Trastuzumab, Pertuzumab, Docetaxel | Fudan University | Breast Cancer | 07/21 | 07/24 | | |
| Active, not recruiting | 3 | 400 | Europe | white light TUR-BT, blue light TUR-BT, optimized MMC, optimized mitomycin-C, single immediate chemotherapy instillation, single instillation | Turku University Hospital, Finnbladder | Bladder Cancer | 12/21 | 08/23 | | |
ACCRUE, NCT04490993: Safety and Efficacy of APL-1202 in Combination With Epirubicin Hydrochloride Versus Epirubicin Hydrochloride Alone in Intermediate and High-risk Chemo-refractory Non-muscle Invasive Bladder Cancer (NMIBC) Patients |
|
|
| Active, not recruiting | 3 | 359 | RoW | APL-1202 in combination with Epirubicin, Placebo in combination with Epirubicin | Jiangsu Yahong Meditech Co., Ltd aka Asieris | Non-muscle Invasive Bladder Cancer | 05/22 | 05/22 | | |
NCT04301739: to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC) |
|
|
| Not yet recruiting | 3 | 522 | NA | HLX10, nab-paclitaxel, carboplatin, doxorubicin or epirubicin and cyclophosphamide, Placebo | Shanghai Henlius Biotech | Triple Negative Breast Cancer | 09/22 | 04/27 | | |
TCTN, NCT02455141: Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer |
|
|
| Recruiting | 3 | 970 | RoW | Epirubicin plus Cyclophosphamide, EC, Taxanes, Taxanes plus Carboplatin | Shanghai Jiao Tong University School of Medicine | Breast Neoplasm | 12/22 | 12/23 | | |
NCT05985187: Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer. |
|
|
| Active, not recruiting | 3 | 412 | RoW | TQB2440 injection + Trastuzumab + Docetaxel, Perjeta + Trastuzumab + Docetaxel | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | HER2-positive Breast Cancer | 01/23 | 12/23 | | |
| Completed | 3 | 278 | Europe, RoW | Carboplatin, Carboplatin Teva, Abraxane, nab-paclitaxel, MPDL3280A, Atezolizumab, Surgery, Anthra | Fondazione Michelangelo | Invasive Ductal Breast Carcinoma | 01/24 | 01/24 | | |
NCT06441110: Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer |
|
|
| Recruiting | 3 | 76 | RoW | Tislelizumab in Combination with Bacillus Calmette-Guérin | Fujian Medical University Union Hospital | Urinary Bladder Neoplasms, BCG Vaccine, Immunotherapy, Active, Multicenter Study, Treatment Outcome, Neoplasm Recurrence, Local | 06/25 | 06/35 | | |
| Recruiting | 3 | 920 | Europe | epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab, anthracycline, taxane, platinum, epirubicin, cyclophosphamide, capecitabine, paclitaxel, carboplatin, pembrolizumab, anthracycline, taxane, antimetabolite, platinum | Lund University Hospital, Swedish Breast Cancer Group, Danish Breast Cancer Cooperative Group, Finnish Breast Cancer Group, Icelandic Breast Cancer Group | Breast Cancer, Triple Negative Breast Neoplasms | 06/23 | 06/35 | | |
IMpassion030, NCT03498716 / 2016-003695-47: A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer |
|
|
| Completed | 3 | 2203 | Europe, Japan, US, RoW | Atezolizumab, Paclitaxel, Dose-dense Doxorubicin or dose-dense Epirubicin, Cyclophosphamide | Hoffmann-La Roche, Breast International Group, Alliance Foundation Trials (AFT), Institut Jules Bordet/Clinical Trials Support Unit (IJB/CTSU), Frontier Science & Technology Research Foundation, Inc. | Triple Negative Breast Cancer | 08/23 | 08/23 | | |
|
|
NCT04103398: TACE Plus Sorafenib Versus TACE Alone for Recurrent Intermediate Hepatocellular Carcinoma |
|
|
| Completed | 3 | 162 | RoW | TACE+sorafenib, TACE | Sun Yat-sen University | Hepatocellular Carcinoma, Sorafenib, Transarterial Chemoembolization | 12/23 | 12/23 | | |
NCT05075460: Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma |
|
|
| Recruiting | 3 | 107 | RoW | Tucidinostat, Azacitidine combined with CHOP | Peking Union Medical College Hospital | T-cell Lymphoma | 05/24 | 10/24 | | |
GeparDouze, NCT03281954 / 2017-002771-25: Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo |
|
|
| Active, not recruiting | 3 | 1550 | Canada, US | Placebo, Atezolizumab | NSABP Foundation Inc, Genentech, Inc., Hoffmann-La Roche | Triple Negative Breast Cancer | 12/24 | 11/27 | | |
|
NCT05164770: Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma |
|
|
| Recruiting | 3 | 160 | RoW | Zanubrutinib+R-CHOP; Zanubrutinib+R-DA-EPOCH; Zanubrutinib+R-HD MTX, R-CHOP; R-DA-EPOCH; R-HD MTX | Shandong Provincial Hospital | High Grade B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, Diffuse Large B Cell Lymphoma, B-cell Non Hodgkin Lymphoma, Mantle Cell Lymphoma | 12/23 | 12/24 | | |
NCT05097443: Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma |
|
|
| Recruiting | 3 | 130 | RoW | Orelabrutinib+R-CHOP; Orelabrutinib+R-DA-EPOCH; Orelabrutinib+R-HD MTX;Orelabrutinib+R+other chemotherapies | Shandong Provincial Hospital | High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, B-cell NonHodgkin Lymphoma | 12/23 | 12/24 | | |
NCT06144944: Neoadjuvant Pyrotinib Versus Placebo Combined With Chemotherapy in HR-positive and HER2-low Early Breast Cancer |
|
|
| Recruiting | 3 | 160 | RoW | Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel, Placebo, epirubicin or doxorubicin, cyclophosphamide, paclitaxel | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Jiangsu HengRui Medicine Co., Ltd. | Breast Cancer Invasive, Hormone-receptor-positive Breast Cancer, HER2 Low Breast Carcinoma, Early-stage Breast Cancer | 06/26 | 12/31 | | |
NCT03876886: The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair Deficiency |
|
|
| Recruiting | 3 | 200 | RoW | Epirubicin, Cyclophosphamide, Paclitaxel, Carboplatin | Chinese Academy of Medical Sciences | Triple Negative Breast Cancer | 02/24 | 12/24 | | |
| Recruiting | 3 | 808 | RoW | Epirubicin, CTX, Paclitaxel, ddEpirubicin, ddCTX, Paclitaxel(with carbo), Carboplatin | Fudan University | Triple-negative Breast Cancer | 06/24 | 06/25 | | |
NCT05121350: A Clinical Trial to Evaluate the Efficacy and Safety of Anotinib Hydrochloride Capsule Combined With Epirubicin Hydrochloride Versus Placebo Combined With Epirubicin Hydrochloride in First-line Treatment of Advanced Soft Tissue Sarcoma |
|
|
| Recruiting | 3 | 256 | RoW | Anlotinib hydrochloride capsule, Epirubicin, Arotinib hydrochloride capsule placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Soft Tissue Sarcoma | 06/24 | 06/24 | | |
ISG-STS-1001, NCT01710176: Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy |
|
|
| Active, not recruiting | 3 | 550 | Europe | epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3), gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8), trabectedin 1.3 mg/m2, high-dose ifosfamide 14 g/m2, given in in 14 days, etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3), gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1) | Italian Sarcoma Group, French Sarcoma Group, Grupo Espanol de Investigacion en Sarcomas | Localized High-risk Soft Tissue Sarcomas of the Extremities and Trunk Wall in Adults | 06/24 | 06/24 | | |
NCT05472896: TACE With Dicycloplatin(TP21) in Unresectable HCC |
|
|
| Recruiting | 3 | 332 | RoW | cTACE, Dicycloplatin (TP21), Epirubicin | Gao-jun Teng | Hepatocellular Carcinoma | 06/24 | 06/24 | | |
TACT2, NCT00301925: Combination Chemotherapy in Treating Patients With Early Stage Breast Cancer That Has Been Removed By Surgery |
|
|
| Active, not recruiting | 3 | 4400 | Europe | pegfilgrastim, capecitabine, cyclophosphamide, epirubicin hydrochloride, fluorouracil, methotrexate, adjuvant therapy | Institute of Cancer Research, United Kingdom | Breast Cancer | 09/24 | 09/24 | | |
NCT05474690: A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer |
|
|
| Withdrawn | 3 | 456 | RoW | Docetaxel + Carboplatin + Trastuzumab + Pertuzumab, TCbHP regimen group, (Epirubicin + Cyclophosphamide - Docetaxel) + (Trastuzumab + Pertuzumab), ECHP-THP regimen group | Henan Cancer Hospital | Breast Cancer, HER2-positive Breast Cancer | 03/23 | 08/24 | | |
Ascertain, NCT04736394: A Phase 3 Study to Evaluate the Safety and Efficacy of APL-1202 as a Single-agent Oral Treatment Versus Intravesical Instillation of Epirubicin Hydrochloride in naïve Intermediate-risk NMIBC Patients |
|
|
| Recruiting | 3 | 800 | RoW | APL-1202, Epirubicin Hydrochloride | Jiangsu Yahong Meditech Co., Ltd aka Asieris | Non-muscle Invasive Bladder Cancer | 03/25 | 12/25 | | |
KEYNOTE-522, NCT03036488 / 2016-004740-11: Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/) |
|
|
| Active, not recruiting | 3 | 1174 | Europe, Canada, Japan, US, RoW | Pembrolizumab, MK-3475, KEYTRUDA®, Carboplatin, PARAPLATIN®, Paclitaxel, TAXOL®, Doxorubicin, ADRIAMYCIN®, Epirubicin, ELLENCE®, Cyclophosphamide, CYTOXAN®, Placebo, Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim, NEUPOGEN®, NEULASTA® | Merck Sharp & Dohme LLC | Triple Negative Breast Neoplasms | 09/25 | 09/25 | | |
|
|
|
|
|
|
|
|
|
|
GENSA, NCT04947059: Effectiveness of an Immediate Postoperative Intravesical Instillation With Either Gemcitabine or Epirubicin in Patients With Urinary Bladder Cancer (Gemcitabine Epirubicin Normal SAline) |
|
|
| Recruiting | 3 | 180 | Europe | Gemcitabine Hydrochloride combined with continuous saline irrigation, GROUP A, Epirubicin Hydrochloride combined with continuous saline irrigation, GROUP B | University of Thessaly | Bladder Cancer | 10/25 | 10/26 | | |
NCT05901428: TCb vs EC-T in High Risk ER+/HER2- Breast Cancer |
|
|
| Recruiting | 3 | 1736 | RoW | Docetaxel, Carboplatin, Epirubicin, Cyclophosphamide | Fudan University | Hormone Receptor Positive HER-2 Negative Breast Cancer | 06/26 | 06/28 | | |
NCT02535221: Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer |
|
|
| Recruiting | 3 | 234 | RoW | Goserelin+TAM+AI, Endocrine therapy, Epirubicin+CTX+5-Fu, Chemotherapy | Peking University | Breast Cancer | 06/26 | 12/26 | | |
NCT05862064: PD-1 Combined With Adjuvant Chemotherapy and Antivascular Therapy Versus Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer |
|
|
| Recruiting | 3 | 606 | RoW | epirubicin,cyclophosphamide,paclitaxel,Carrelizumab, epirubicin,cyclophosphamide,paclitaxel | Fudan University | TNBC - Triple-Negative Breast Cancer | 07/26 | 07/28 | | |
NCT05678933: AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH |
|
|
| Enrolling by invitation | 3 | 200 | RoW | Azacitidine, Chidamide, Cyclophosphamide, Epirubicin, Vincristine, Prednisone | Tianjin Medical University Cancer Institute and Hospital | Peripheral T-cell Lymphoma Targeted Therapy | 12/27 | 12/29 | | |
TROPION-Breast04, NCT06112379: A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer |
|
|
| Recruiting | 3 | 1728 | Europe, Canada, Japan, US, RoW | Dato-DXd, Datopotamab deruxtecan (Dato-DXd, DS-1062a), Durvalumab, MEDI4736, Pembrolizumab, KEYTRUDA®, Doxorubicin, Epirubicin, Cyclophosphamide, Paclitaxel, Carboplatin, Capecitabine, XELODA®, Capecitabine Cell Pharm, Capecitabine EG, Capecitabine Accord, Olaparib, LYNPARZA® | AstraZeneca, Daiichi Sankyo | Breast Cancer | 03/28 | 08/30 | | |
KEYNOTE-756, NCT03725059 / 2017-004869-27: Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/) |
|
|
| Active, not recruiting | 3 | 1240 | Europe, Canada, Japan, US, RoW | Pembrolizumab (K), MK-3475, KEYTRUDA®, Placebo (P), Paclitaxel (X), TAXOL®, Doxorubicin (A), ADRIAMYCIN®, Epirubicin (E), ELLENCE®, Cyclophosphamide (C), CYTOXAN®, Endocrine therapy, Radiation therapy, Surgery | Merck Sharp & Dohme LLC | Breast Cancer | 01/31 | 01/31 | | |
|
|
NCT05883852: EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer |
|
|
| Recruiting | 3 | 1406 | RoW | Docetaxel, carboplatin, Trastuzumab, Pertuzumab, Epirubicin, cyclophosphamide | Fudan University | HER2 Positive Early Breast Cancer | 07/31 | 07/31 | | |
2006-006088-22: Prospective multicenter phase III clinical trial using cytoreductive surgery with hyperthermic intraoperative chemotherapy (HIPEC) after preoperative chemotherapy in patients with peritoneal carcinomatosis of gastric cancer incl. adenocarcinoma of the esophagogastreal junction Prospektive multizentrische Phase III-Studie zur zytoreduktiven Chirurgie mit hyperthermer intraperitonealer Chemoperfusion nach präoperativer Chemotherapie beim Magenkarzinom inkl. AEG mit primärer peritonealer Metastasierung (Gastripec I) |
|
|
| Ongoing | 2/3 | 180 | Europe | Epirubicin, Oxaliplatin, capecitabin, Cisplatin, Trastuzumab, Mitomycin, Solution for infusion, Concentrate for solution for infusion, Tablet, Powder for infusion | Klinik für Chirurgie, Charité Campus Virchow-Klinikum, Deutsche Krebshilfe | Peritoneal carcinomatosis of gastric cancer incl. adenocarcinoma of the esophagogastreal junction Peritoneal metastasiertes Magenkarzinom inkl. AEG, Peritoneal carcinomatosis of gastric cancer incl. adenocarcinoma of the esophagogastreal junction Peritoneal metastasiertes Magenkarzinom inkl. AEG, Diseases [C] - Cancer [C04] | | | | |
2011-001462-17: Trial for the optimisation of risk assessment and therapy success predicition in patients with early breast cancer by the use of biomarkers in advance to therapy decission-making to personalize therapies. |
|
|
| Ongoing | 2/3 | 5236 | Europe | Epirubicin, Cyclophosphamide, Paclitaxel, Tamoxifen, Anastrozole, Letrozole, Exemestan, trastuzumab emtansine (T-DM1), Trastuzumab, Paclitaxel-Albumin, Gemcitabine, Carboplatin, Pertuzumab, Myocet, RO530-4020/xxx, RO4368451, Concentrate for solution for infusion, Tablet, Powder for concentrate for solution for infusion, Powder for solution for infusion, Kadcyla, Herceptin 150 mg, Abraxane, Perjeta | Westdeutsche Studiengruppe GmbH, Genomic Health , Inc., Roche Pharma AG, Celgene Corp., Amgen, TEVA GmbH, Bayer AG | Early primary breast cancer, hormone receptor positve or negative, HER2 positive or negative, any nodal status., Early diagnosed breast cancer at first occurence, with hormone receptor over-expressing tumor and any lymph node involvement (from none to any)., Diseases [C] - Cancer [C04] | | | | |
ACTRN12613000206729: A Randomized, Multi-Centre, Open-Label Study of Neo-adjuvant Taxanes and Capecitabine(TX) versus Taxanes and Anthracycline(TA) for Breast Cancer |
|
|
| Terminated | 2/3 | 400 | | | Peking University People's Hospital Breast Center, Chinese Anti-Cancer Association Committee of Breast Cancer Society | Breast cancer, Neoadjuvant chemotherpy | | | | |
ADAPT, NCT01779206: - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer |
|
|
| Active, not recruiting | 2/3 | 4936 | Europe | Epirubicin, Cyclophosphamide, Docetaxel, Paclitaxel | West German Study Group | Breast Cancer | 09/19 | 10/24 | | |
|
| Recruiting | 2/3 | 60 | Canada | (Epirubicin Cisplatin 5-Fluorouracil / Xeloda) OR 5-Fluorouracil Leucovorin Oxaliplatin Docetaxel, ECF/ECX or FLOT, Carboplatin paclitaxel plus concurrent radiotherapy | Dr. Gordon Buduhan, CancerCare Manitoba, University of Toronto, London Health Sciences Centre | Esophageal Cancer, Adenocarcinoma, Esophageal, Adenocarcinoma, Gastroesophageal Junction | 06/21 | 06/22 | | |
ACTRN12609000035224: TOP GEAR: Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma
A randomised phase II/III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer |
|
|
| Active, not recruiting | 2/3 | 570 | | | Australasian Gastro-Intestinal Trials Group (AGITG), Cancer Australia through The Priority-driven Collaborative Cancer Research Scheme, Cancer Council Australia, National Health and Medical Research Council | Resectable Gastric Cancer | | | | |
NCT04290793: Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer |
|
|
| Not yet recruiting | 2/3 | 280 | NA | Pyrotinib, Epirubicin, Cyclophosphamide, Taxanes, Trastuzumab | Hebei Medical University Fourth Hospital | Breast Cancer | 03/22 | 03/24 | | |
NCT05253066: Chidamide Combined With Exemestane (+/- Goserelin) Versus Neoadjuvant Chemotherapy in Patients of Stage II-III HR-positive/HER2-negative Breast Cancer |
|
|
| Not yet recruiting | 2/3 | 130 | NA | Chidamide combined with exemestane (+/- goserelin), Chemotherapy with docetaxel plus epirubicin or change of chemotherapy regimen (at the discretion of the clinician) | Shengjing Hospital | Breast Neoplasms | 07/22 | 01/25 | | |
NCT04576143: Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer |
|
|
| Recruiting | 2/3 | 260 | RoW | Epirubicin, Epirubicin Hydrochloride, Cyclophosphamid, CTX, Docetaxel, Paclitaxel, PTX | Second Affiliated Hospital, School of Medicine, Zhejiang University, Women's Hospital School Of Medicine Zhejiang University, Changxing People's Hospital, Zhejiang Provincial People's Hospital, Hangzhou First People's Hospital, School of Medicine, Zhejiang Universiry, Huizhou Municipal Central Hospital | HER2-negative Breast Cancer, Neoadjuvant Chemotherapy | 06/23 | 09/27 | | |
BCTOP-T-A01, NCT02641847: TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature |
|
|
| Active, not recruiting | 2/3 | 503 | RoW | docetaxel, doxorubicin or epirubicin, cyclophosphamide, gemcitabine, cisplatin | Fudan University | Triple Negative Breast Cancer, Breast Cancer | 12/23 | 12/27 | | |
NCT06009627: Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients |
|
|
| Recruiting | 2/3 | 119 | RoW | Dalcelli、Exemestane、Gosserine, Docetaxel for injection、Epirubicin hydrochloride for injection、Cyclophosphamide for injection | Tianjin Medical University Cancer Institute and Hospital | Breast Cancer | 03/25 | 09/26 | | |
| Active, not recruiting | 2/3 | 574 | RoW | Epirubicin + cisplatin + 5-fluorouracil OR epirubicin + cisplatin + capecitabine OR epirubicin + oxaliplatin + capecitabine OR 5-Fluorouracil + leucovorin + oxaliplatin + docetaxel, Epirubicin hydrochloride, Pharmorubicin, Ellence, Platinol, 5-FU, Adrucil, Carac, Efudex. Efudix, Xeloda, Eloxatin, Folinic acid, 5-formyl tetrahydrofolic acid, Citrovorum Factor, Taxotere, Docetere, Preoperative chemoradiotherapy, Gastric resection | Australasian Gastro-Intestinal Trials Group, National Health and Medical Research Council, Australia, Trans Tasman Radiation Oncology Group, European Organisation for Research and Treatment of Cancer - EORTC, NCIC Clinical Trials Group | Gastric Cancer | 12/26 | 12/26 | | |
ChiCTR2000040585: A randomized, controlled, single-center clinical trial assessing the efficacy and safety of pegylated liposomal doxorubicin combined with docetaxel versus epirubicin combined with docetaxel in neoadjuvant treatment of triple-negative breast cancer |
|
|
| Not yet recruiting | 2/3 | 156 | | PLD combined with docetaxel ;epirubicin combined with docetaxel | Southwest Hospital, Army Medical University; Southwest Hospital, Army Medical University, Self-raising | Triple negative breast cancer | | | | |
RC48-C024, CTR20231476: A randomized, open-label, multicenter phase II clinical study evaluating the efficacy and safety of vedicitumab alone or in combination with toripalimab or sequential chemotherapy in patients with HR-negative, HER2-low breast cancer |
|
|
| Ongoing | 2 | | China | Aidixi (disitamab vedotin) - Rongchang Pharma, Pfizer, Loqtorzi (toripalimab) - Shanghai Junshi Biosci, Coherus Biosci, carboplatin - Generic mfg., epirubicin - Generic mfg., cyclophosphamide - Generic mfg. | Remegen Biopharmaceutical (Yantai) Co., Ltd | HR-negative, HER2-low breast cancer | | | | |
